Vincent-Genod, D., Rippert, P., Coton, J., Le Goff, L., Barriere, A., Berruyer, A., Bernard, M., Garde, C., Gutierrez-Garcia, M., Gilabert, S., Gomes-Lisboade-Souza, A., Daron, A., Servais, L., Thomann, G., & Vuillerot, C. (26 October 2022). Scoring People With Spinal Muscular Atrophy on the Motor Function Measure Using the Microsoft Kinect. Pediatric Physical Therapy, Publish Ahead of Print. doi:10.1097/PEP.0000000000000968 |
Monseur, A., Carlin, B. P., Boulanger, B., Seferian, A., Servais, L., Freitag, C., Thielemans, L., Gidaro, T., Gargaun, E., Chê, V., Schara, U., Gangfuß, A., D’Amico, A., Dowling, J. J., Darras, B. T., Daron, A., Hernandez, A., de Lattre, C., Arnal, J.-M., ... the NatHis-MTM Study Group. (July 2022). Leveraging Natural History Data in One- and Two-Arm Hierarchical Bayesian Studies of Rare Disease Progression. Statistics in Biosciences, 14 (2), 237 - 258. doi:10.1007/s12561-021-09323-5 |
Mercuri, E., Deconinck, N., Mazzone, E. S., Nascimento, A., Oskoui, M., Saito, K., Vuillerot, C., Baranello, G., Boespflug-Tanguy, O., Goemans, N., Kirschner, J., Kostera-Pruszczyk, A., Servais, L., Gerber, M., Gorni, K., Khwaja, O., Kletzl, H., Scalco, R. S., Staunton, H., ... Daron, A. (April 2022). Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurology, 21 (1), 42-52. doi:10.1016/S1474-4422(21)00367-7 |
Poleur, M., Annoussamy, M., Eggenspieler, D., DELSTANCHE, S., DARON, A., & Servais, L. (October 2021). SMA – OUTCOME MEASURES AND REGISTRIES. Neuromuscular Disorders, 31, 130. doi:10.1016/j.nmd.2021.07.290 |
Poleur, M., Ulinici, A., DARON, A., Schneider, O., Farra, F. D., Demonceau, M., Annoussamy, M., Vissière, D., Eggenspieler, D., & Servais, L. (October 2021). DMD/BMD – OUTCOME MEASURES. Neuromuscular Disorders, 31, 86-S87. doi:10.1016/j.nmd.2021.07.149 |
Poleur, M., Ulinici, A., DARON, A., Schneider, O., Dal Farra, F., Demonceau, M., Annoussamy, M., Vissière, D., Eggenspieler, D., & Servais, L. (2021). Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment. Orphanet Journal of Rare Diseases. doi:10.1186/s13023-021-01956-5 |
Servais, L., Baranello, G., Scoto, M., DARON, A., & Oskoui, M. (May 2021). Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities. Expert Opinion on Investigational Drugs, 30 (5), 519-527. doi:10.1080/13543784.2021.1904889 |
Annoussamy, M., Seferian, A. M., DARON, A., Péréon, Y., Cances, C., Vuillerot, C., De Waele, L., Laugel, V., Schara, U., Gidaro, T., Lilien, C., Hogrel, J.-Y., Carlier, P., Fournier, E., Lowes, L., Gorni, K., Ly-Le Moal, M., Hellbach, N., Seabrook, T., ... Servais, L. (February 2021). Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Annals of Clinical and Translational Neurology, 8 (2), 359-373. doi:10.1002/acn3.51281 |
BOEMER, F., Caberg, J.-H., Beckers, P., Dideberg, V., di Fiore, S., Bours, V., Marie, S., Dewulf, J., Marcelis, L., Deconinck, N., Daron, A., Blasco-Perez, L., Tizzano, E., Hiligsmann, M., Lombet, J., Pereira, T., Lopez-Granados, L., Shalchian-Tehran, S., van Assche, V., ... Servais, L. (2021). Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Scientific Reports, 11 (1), 19922. doi:10.1038/s41598-021-99496-2 |
Mercuri, E., Muntoni, F., Baranello, G., Masson, R., Boespflug-Tanguy, O., Bruno, C., Corti, S., DARON, A., Deconinck, N., Servais, L., Straub, V., Ouyang, H., Chand, D., Tauscher-Wisniewski, S., Mendonca, N., & Lavrov, A. (2021). Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurology, 20 (10), 832-841. doi:10.1016/S1474-4422(21)00251-9 |
Materne, C., Hudon, L., DARON, A., & Demarche, M. (July 2020). Myasthénie auto-immune juvénile. Revue Médicale de Liège, 75 (7-8), 524-528. |
Aragon-Gawinska, K., DARON, A., Ulinici, A., Vanden Brande, L., Seferian, A., Gidaro, T., Scoto, M., Deconinck, N., & Servais, L. (March 2020). Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen. Developmental Medicine and Child Neurology, 62 (3), 310-314. doi:10.1111/dmcn.14412 |
Almeida Ribeiro, M., Bouchard, S., Dupuis, G., Daron, A., & Stassart, C. (20 May 2019). Sentiment de présence et symptômes de cybermalaise dans une population d’enfants souffrant de maux de tête chroniques immergés en réalité virtuelle. Poster session presented at La qualité de vie au cœur des soins de première ligne : évaluations, applications et perspectives de vie, Liège, Belgium. |
Annoussamy, M., Lilien, C., Gidaro, T., Gargaun, E., Che, V., Schara, U., Gangfuss, A., D'Amico, A., Dowling, J. J., Darras, B. T., Daron, A., Hernandez, A., de Lattre, C., Arnal, J.-M., Mayer, M., Cuisset, J.-M., Vuillerot, C., Fontaine, S., Bellance, R., ... Servais, L. (16 April 2019). X-linked myotubular myopathy: A prospective international natural history study. Neurology, 92 (16), 1852-e1867. doi:10.1212/WNL.0000000000007319 |
Daron, A., DELSTANCHE, S., Dangouloff, T., & Servais, L. (February 2019). Amyotrophie spinale infantile (R)évolution thérapeutique. Revue Médicale de Liège, 74 (2), 82-85. |
Annoussamy, M., Grangé, A., Lilien, C., Chê, V., Duchêne, D., Gidaro, T., Behin, A., Baets, J., D'Amico, A., DARON, A., Bitoun, M., Paradis, K., Thielemans, L., Van Rooijen, S., & Servais, L. (October 2018). Baseline characteristics of patients with centronuclear myopathy due to mutations in DNM2 gene enrolled in a European prospective natural history study. Poster session presented at WMS Congress 2018, Mendoza, Argentina. |
Annoussamy, M., Lilien, C., Gidaro, T., Chê, V., Schara, U., D'Amico, A., Dowling, J., Darras, B., DARON, A., Mayer, M., Hernandez, A., Vuillerot, C., Fontaine, S., de Lattre, C., Bellance, R., Biancalana, V., Buj-Bello, A., Hogrel, J., Landy, H., ... NatHis-MTM Study Group. (October 2018). Clinical changes over time in a European and North-American cohort of patients with X-linked Myotubular Myopathy. Poster session presented at WMS Congress 2018, Mendoza, Argentina. |
Aragon-Gawinska, K., Seferian, A. M., DARON, A., Gargaun, E., Vuillerot, C., Cances, C., Ropars, J., Chouchane, M., Cuppen, I., Hughes, I., Illingworth, M., Marini-Bettolo, C., Rambaud, J., Taytard, J., Annoussamy, M., Scoto, M., Gidaro, T., & Servais, L. (October 2018). Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study. Neurology, 91 (14), 1312-e1318. doi:10.1212/WNL.0000000000006281 |
Aragon-Gawinska, K., Seferian, A., Vanden Brande, L., DARON, A., Ulinici, Deconinck, N., Annoussamy, M., Vuillerot, C., Cances, C., Ropars, J., Chouchane, M., Balintova, Z., Modrzejewska, S., Cuppen, I., Hughes, I., Illingworth, M., Marini-Bettolo, C., White, K., Scoto, M., ... Servais, L. (October 2018). Treatment by nusinersen in spinal muscular atrophy type 1 patients older than 7 months, 14 months follow-up. Poster session presented at WMS Congress 2018, Mendoza, Argentina. |
Chabanon, A., Annoussamy, M., DARON, A., Péréon, Y., Cances, C., Vuillerot, C., Goemans, N., Cuisset, J., Laugel, V., Schara, U., Gidaro, T., Seferian, A., Lowes, L., Carlier, P., Hogrel, J., Czech, C., Hermosilla, O., Kwaja, O., & Servais, L. (October 2018). Two years, longitudinal data of the European prospective natural history study of patients with type 2 and 3 spinal muscular atrophy. Poster session presented at WMS Congress 2018, Mendoza, Argentina. |
Hogrel, J., Annoussamy, M., Chabanon, A., DARON, A., Péréon, Y., Cances, C., Vuillerot, C., Goemans, N., Cuisset, J., Laugel, V., Schara, U., Gargaun, E., Gidaro, T., Seferian, A., Turk, S., Hermosilla, R., Fournier, E., Baudin, P., Carlier, P., & Servais, L. (October 2018). Associations between NMR, electrophysiological, strength and function variables in SMA type 2 and 3. Poster session presented at WMS Congress, Mendoza, Argentina. |
Chabanon, A., Seferian, A. M., DARON, A., Pereon, Y., Cances, C., Vuillerot, C., De Waele, L., Cuisset, J.-M., Laugel, V., Schara, U., Gidaro, T., Gilabert, S., Hogrel, J.-Y., Baudin, P.-Y., Carlier, P., Fournier, E., Lowes, L. P., Hellbach, N., Seabrook, T., ... Servais, L. (July 2018). Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study. PLoS ONE, 13 (7), 0201004. doi:10.1371/journal.pone.0201004 |
LEROY, P., DARON, A., & DEPIERREUX, F. (25 March 2017). Dystonie de type 11 à début précoce. Paper presented at 45ème Réunion de la Société Européenne de Neuropédiatrie (2017), Turin, Italy. |
DARON, A., DRESSE, M.-F., Hoyoux, C., Tebache, M., MISSON, J.-P., & DEBRAY, F.-G. (2015). Schizencephaly associated with a severe prothrombotic syndrome caused by antithombin III deficiency. Tijdschrift van de Belgische Kinderarts, 17 (1), 109. |
MAGIS, D., Boon, E., Coppola, G., DARON, A., & Schoenen, J. (2012). A novel CACNA1A mutation results in episodic ataxia with migrainous features without headache. Cephalalgia. doi:10.1177/0333102412459572 |
Vaessen, S., DARON, A., DUBRU, J.-M., Ebetiuc, I., Leroy, P., & Misson, J.-P. (2012). Aspects neurologiques associés au Syndrome de Down. Tijdschrift van de Belgische Kinderarts, 14 (2), 40-43. |
Mohring, M.-P., Dadoumont, C., DARON, A., Leroy, P., & Misson, J.-P. (2007). Intoxication au CO: Mouvements athétosiques. Journal de Pédiatrie belge. |
DARON, A., Leroy, P., & Misson, J.-P. (2005). A propos d'un cas d'hémiparésie aigue chez l'enfant. Percentile, 10, 29. |
Leroy, P., DARON, A., Weerts, E., Born, J.-D., & Misson, J.-P. (2005). Encéphalocéle frontoethimoidale: Encéphalite herpétique comme premier signe d'une méningite récurrente. Revista de Neurologia. |
Piette, C., DARON, A., Leroy, P., Gougnard, T., & Minon, J.-M. (2005). Intoxicatin à la cyproheptadine: un cas clinique. Paper presented at Annual meeting of the French Society of Clinical Toxicology. |